Sickle Cell Disease Clinical Trials in Richmond, Virginia

5 studies are recruiting for sickle cell disease in Richmond, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Virginia Comm Univ Medical Ctr, Richmond, Virginia

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Virginia Comm Univ Medical Ctr, Richmond, Virginia

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

3. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

   This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigili…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Locations

   16 in total

   Run by

   CSL Behring

   See if you can join NCT07224360 on ClinicalTrials.gov

4. The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

   This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study detai…

   Stage

   Phase 3

   Ages

   10 to 65

   Site

   VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400012, Richmond, Virginia

   Locations

   53 in total

   Run by

   Sanofi

   See if you can join NCT06975865 on ClinicalTrials.gov

5. Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

   The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also s…

   Stage

   Not phased

   Ages

   16 to 30

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Locations

   14 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06374238 on ClinicalTrials.gov